Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-6201 in Sarcoma and Selected Solid Tumors
NCT07374848Phase 1Recruiting
- Sponsor
- Zai Lab
- Start
- Mar 2026
- Primary completion
- Aug 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZL-6201 in sarcoma and solid tumor, sponsored by Zai Lab. Primary endpoints: Incidence of Dose Limiting Toxicities at 3 weeks, Incidence of Treatment Emergent Adverse Events at 36 months and 4 more. Started Mar 2026; status: recruiting.
02
Drugs
ZL-6201
03
Conditions
sarcomasolid tumor
Beyond the preview
Go deeper on NCT07374848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374848.